Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer

Paul R. Kucera, Michael L. Herman, Paul Treadwell, Ellen E. Sheets, John P. Micha, Mark A. Rettenmaier, Martin Colman, Philip J. Disaia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sixteen patients with advanced epithelial ovarian cancer who were treated with cytoreductive surgery followed by multiagent chemotherapy were found to have residual tumor masses less than 2 cm in greatest diameter at reexploration and were treated with whole-abdominal radiation (19-31 Gy). Thirteen patients also received pelvic boosts to a total pelvic dose of 41-53.7 Gy. Radiotherapy was completed in all but 2 patients after treatment delays in 7 patients. Early treatment complications included myelosuppression in 11 patients, diarrhea in 3, and a self-limited small bowel obstruction in one. Delayed complications were severe and included 9 patients with radiation enterocolitis, 8 of whom required intestinal resection or diversion. One additional patient with radiation cystitis required instillation of formalin to control bleeding. Two patients are without evidence of disease 28 and 30 months following radiotherapy, while the remaining 14 patients have recurred after a median progression-free interval of 9 months (range 1-30 months). All patients who recurred failed within the treatment field and died of cancer after a median interval of 19 months following radiotherapy and 9 months after documentation of progression. These data suggest that few patients with persistent ovarian cancer following surgery and chemotherapy will be salvaged with radiotherapy.

Original languageEnglish (US)
Pages (from-to)338-342
Number of pages5
JournalGynecologic Oncology
Volume36
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Radiotherapy
Radiation
Ovarian epithelial cancer
Enterocolitis
Drug Therapy
Cystitis
Residual Neoplasm
Documentation
Ovarian Neoplasms
Formaldehyde
Diarrhea
Therapeutics
Hemorrhage

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Kucera, P. R., Herman, M. L., Treadwell, P., Sheets, E. E., Micha, J. P., Rettenmaier, M. A., ... Disaia, P. J. (1990). Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Gynecologic Oncology, 36(3), 338-342. https://doi.org/10.1016/0090-8258(90)90138-B

Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. / Kucera, Paul R.; Herman, Michael L.; Treadwell, Paul; Sheets, Ellen E.; Micha, John P.; Rettenmaier, Mark A.; Colman, Martin; Disaia, Philip J.

In: Gynecologic Oncology, Vol. 36, No. 3, 1990, p. 338-342.

Research output: Contribution to journalArticle

Kucera, PR, Herman, ML, Treadwell, P, Sheets, EE, Micha, JP, Rettenmaier, MA, Colman, M & Disaia, PJ 1990, 'Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer', Gynecologic Oncology, vol. 36, no. 3, pp. 338-342. https://doi.org/10.1016/0090-8258(90)90138-B
Kucera PR, Herman ML, Treadwell P, Sheets EE, Micha JP, Rettenmaier MA et al. Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Gynecologic Oncology. 1990;36(3):338-342. https://doi.org/10.1016/0090-8258(90)90138-B
Kucera, Paul R. ; Herman, Michael L. ; Treadwell, Paul ; Sheets, Ellen E. ; Micha, John P. ; Rettenmaier, Mark A. ; Colman, Martin ; Disaia, Philip J. / Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. In: Gynecologic Oncology. 1990 ; Vol. 36, No. 3. pp. 338-342.
@article{539edb53e65a40b5839a987637227582,
title = "Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer",
abstract = "Sixteen patients with advanced epithelial ovarian cancer who were treated with cytoreductive surgery followed by multiagent chemotherapy were found to have residual tumor masses less than 2 cm in greatest diameter at reexploration and were treated with whole-abdominal radiation (19-31 Gy). Thirteen patients also received pelvic boosts to a total pelvic dose of 41-53.7 Gy. Radiotherapy was completed in all but 2 patients after treatment delays in 7 patients. Early treatment complications included myelosuppression in 11 patients, diarrhea in 3, and a self-limited small bowel obstruction in one. Delayed complications were severe and included 9 patients with radiation enterocolitis, 8 of whom required intestinal resection or diversion. One additional patient with radiation cystitis required instillation of formalin to control bleeding. Two patients are without evidence of disease 28 and 30 months following radiotherapy, while the remaining 14 patients have recurred after a median progression-free interval of 9 months (range 1-30 months). All patients who recurred failed within the treatment field and died of cancer after a median interval of 19 months following radiotherapy and 9 months after documentation of progression. These data suggest that few patients with persistent ovarian cancer following surgery and chemotherapy will be salvaged with radiotherapy.",
author = "Kucera, {Paul R.} and Herman, {Michael L.} and Paul Treadwell and Sheets, {Ellen E.} and Micha, {John P.} and Rettenmaier, {Mark A.} and Martin Colman and Disaia, {Philip J.}",
year = "1990",
doi = "10.1016/0090-8258(90)90138-B",
language = "English (US)",
volume = "36",
pages = "338--342",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer

AU - Kucera, Paul R.

AU - Herman, Michael L.

AU - Treadwell, Paul

AU - Sheets, Ellen E.

AU - Micha, John P.

AU - Rettenmaier, Mark A.

AU - Colman, Martin

AU - Disaia, Philip J.

PY - 1990

Y1 - 1990

N2 - Sixteen patients with advanced epithelial ovarian cancer who were treated with cytoreductive surgery followed by multiagent chemotherapy were found to have residual tumor masses less than 2 cm in greatest diameter at reexploration and were treated with whole-abdominal radiation (19-31 Gy). Thirteen patients also received pelvic boosts to a total pelvic dose of 41-53.7 Gy. Radiotherapy was completed in all but 2 patients after treatment delays in 7 patients. Early treatment complications included myelosuppression in 11 patients, diarrhea in 3, and a self-limited small bowel obstruction in one. Delayed complications were severe and included 9 patients with radiation enterocolitis, 8 of whom required intestinal resection or diversion. One additional patient with radiation cystitis required instillation of formalin to control bleeding. Two patients are without evidence of disease 28 and 30 months following radiotherapy, while the remaining 14 patients have recurred after a median progression-free interval of 9 months (range 1-30 months). All patients who recurred failed within the treatment field and died of cancer after a median interval of 19 months following radiotherapy and 9 months after documentation of progression. These data suggest that few patients with persistent ovarian cancer following surgery and chemotherapy will be salvaged with radiotherapy.

AB - Sixteen patients with advanced epithelial ovarian cancer who were treated with cytoreductive surgery followed by multiagent chemotherapy were found to have residual tumor masses less than 2 cm in greatest diameter at reexploration and were treated with whole-abdominal radiation (19-31 Gy). Thirteen patients also received pelvic boosts to a total pelvic dose of 41-53.7 Gy. Radiotherapy was completed in all but 2 patients after treatment delays in 7 patients. Early treatment complications included myelosuppression in 11 patients, diarrhea in 3, and a self-limited small bowel obstruction in one. Delayed complications were severe and included 9 patients with radiation enterocolitis, 8 of whom required intestinal resection or diversion. One additional patient with radiation cystitis required instillation of formalin to control bleeding. Two patients are without evidence of disease 28 and 30 months following radiotherapy, while the remaining 14 patients have recurred after a median progression-free interval of 9 months (range 1-30 months). All patients who recurred failed within the treatment field and died of cancer after a median interval of 19 months following radiotherapy and 9 months after documentation of progression. These data suggest that few patients with persistent ovarian cancer following surgery and chemotherapy will be salvaged with radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025247968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025247968&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90138-B

DO - 10.1016/0090-8258(90)90138-B

M3 - Article

C2 - 2318442

AN - SCOPUS:0025247968

VL - 36

SP - 338

EP - 342

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -